Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $2 | $3 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $2 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 9.8% | 2.1% | 2.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 48.5% | 46.8% | 52.2% | 54% |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 6.1% | 9.7% | 29.4% | -75.4% |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 8.6% | 4.4% | 10.4% | -73% |
| EPS Diluted | 1.43 | 0.68 | 1.55 | -10.49 |
| % Growth | 110.3% | -56.1% | 114.8% | – |
| Operating Cash Flow | $0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |